Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study
Abstract
In a prospective study of an estimated 9,792 inpatients treated with neuroleptic medication at a large Chinese psychiatric hospital, 12 patients developed neuroleptic malignant syndrome. The estimated prevalence of neuroleptic malignant syndrome in these psychiatric inpatients was 1.23/1,000 (95% confidence interval = 0.63/1,000 to 2.14/1,000). Unlike other investigators, the authors found that young adulthood, nonschizophrenic illness, oral high-potency neuroleptics, and concurrent use of lithium were not important risk factors for neuroleptic malignant syndrome. However, depot fluphenazine decanoate, particularly if used without an antiparkinsonian agent, was a risk factor.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
